Interleukin-21 (IL-21) is a recently discovered cytokine and plays critical roles in antitumor immune responses. Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. In this study, we investigated the association between IL-21 genetic polymorphisms and the susceptibility to DLBCL, and the possible functions of these polymorphisms. Two IL-21 polymorphisms, rs907715G/A and rs2221903A/G, were examined in 212 DLBCL patients and 232 healthy controls. Data showed that percentages of rs907715GA and AA genotypes were significantly lower in patients than in controls (odds ratio [OR]=0.60, 95% confidence interval [CI]: 0.40–0.90, p=0.014; OR=0.31, 95% CI: 0.17–0.56, p<0.001, respectively). Frequency of the rs2221903A/G polymorphism did not reveal any significant differences between patients and healthy donors. Further analyses demonstrated a significantly decreased number of rs907715AA genotype in patients with advanced Ann Arbor stages (III+IV). Moreover, we investigated the correlation between IL-21 polymorphisms and serum level of IL-21. Results showed that subjects carrying rs907715AA had significantly increased level of IL-21 than those with GG genotype or GA genotype. These data suggest that rs907715G/A polymorphism may act as a protective factor of DLBCL and might affect the serum level of IL-21.
Get full access to this article
View all access options for this article.
References
1.
AkamatsuN., YamadaY., HasegawaH., MakabeK., AsanoR., KumagaiI., MurataK., ImaizumiY., TsukasakiK., TsurudaK., SugaharaK., AtogamiS., YanagiharaK., and KamihiraS. (2007). High IL-21 receptor expression and apoptosis induction by IL-21 in follicular lymphoma. Cancer Lett, 256, 196–206.
2.
AndorskyD.J., and TimmermanJ.M. (2008). Interleukin-21: biology and application to cancer therapy. Exp Opin Biol Ther, 8, 1295–1307.
3.
BelleraC., PraudD., Petit-MonegerA., McKelvie-SebileauP., SoubeyranP., and Mathoulin-PelissierS. (2013). Barriers to inclusion of older adults in randomised controlled clinical trials on Non-Hodgkin's lymphoma: a systematic review. Cancer Treat Rev, 39, 812–817.
4.
BrenneA.T., RoT.B., WaageA., SundanA., BorsetM., and Hjorth-HansenH. (2002). Interleukin-21 is a growth and survival factor for human myeloma cells. Blood, 99, 3756–3762.
5.
ChaZ., GuH., GuoH., TuX., ZangY., ZhaoC., HuaM., RechlicJ.R., OlasnovaL.M., SongH., and QianB. (2014). Effect of interleukin 21 and its receptor on CD8 T cells in the pathogenesis of diffuse large B-cell lymphoma. Oncology Lett, 8, 421–425.
6.
ChenQ., YangW., GuptaS., BiswasP., SmithP., BhagatG., and PernisA.B. (2008). IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor. Immunity, 29, 899–911.
7.
DienBard, J., GelebartP., AnandM., ZakZ., HegazyS.A., AminH.M., and LaiR. (2009). IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma. Am J Pathol, 175, 825–834.
8.
DingL., WangS., ChenG.M., LengR.X., PanH.F., and YeD.Q. (2012). A single nucleotide polymorphism of IL-21 gene is associated with systemic lupus erythematosus in a Chinese population. Inflammation, 35, 1781–1785.
9.
GelebartP., ZakZ., AnandM., Dien-BardJ., AminH.M., and LaiR. (2009). Interleukin-21 effectively induces apoptosis in mantle cell lymphoma through a STAT1-dependent mechanism. Leukemia, 23, 1836–1846.
10.
JiaH.Y., ZhangZ.G., GuX.J., GuoT., CuiB., NingG., and ZhaoY.J. (2011). Association between interleukin 21 and Graves' disease. Genet Mol Res, 10, 3338–3346.
11.
JinH., CarrioR., YuA., and MalekT.R. (2004). Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J Immunol, 173, 657–665.
12.
LanY., LuoB., WangJ.L., JiangY.W., and WeiY.S. (2014). The association of interleukin-21 polymorphisms with interleukin-21 serum levels and risk of systemic lupus erythematosus. Gene, 538, 94–98.
13.
LiG., XuR., CaoY., XieX., and ZhengZ. (2014). Interleukin-21 polymorphism affects gene expression and is associated with risk of ischemic stroke. Inflammation [Epub ahead of print]; DOI: 10.1007/s10753-014-9935-9.
14.
Macias-PerezI.M., and FlinnI.W. (2012). B-cell receptor pathobiology and targeting in NHL. Curr Oncol Rep, 14, 411–418.
15.
MorozA., EppolitoC., LiQ., TaoJ., CleggC.H., and ShrikantP.A. (2004). IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol, 173, 900–909.
16.
NurievaR.I., ChungY., HwangD., YangX.O., KangH.S., MaL., WangY.H., WatowichS.S., JettenA.M., TianQ., and DongC. (2008). Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity, 29, 138–149.
17.
NuttS.L., BradyJ., HayakawaY., and SmythM.J. (2004). Interleukin 21: a key player in lymphocyte maturation. Crit Rev Immunol, 24, 239–250.
18.
OzakiK., KiklyK., MichalovichD., YoungP.R., and LeonardW.J. (2000). Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci U S A, 97, 11439–11444.
19.
Parrish-NovakJ., DillonS.R., NelsonA., HammondA., SprecherC., GrossJ.A., JohnstonJ., MaddenK., XuW., WestJ., SchraderS., BurkheadS., HeipelM., BrandtC., KuijperJ.L., KramerJ., ConklinD., PresnellS.R., BerryJ., ShiotaF., BortS., HamblyK., MudriS., CleggC., MooreM., GrantF.J., Lofton-DayC., GilbertT., RayondF., ChingA., YaoL., SmithD., WebsterP., WhitmoreT., MaurerM., KaushanskyK., HollyR.D., and FosterD. (2000). Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature, 408, 57–63.
20.
Parrish-NovakJ., FosterD.C., HollyR.D., and CleggC.H. (2002). Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leuk Biol, 72, 856–863.
21.
SongH., ChenL., ChaZ., and BaiJ. (2012). Interleukin 2 gene polymorphisms are associated with non-Hodgkin lymphoma. DNA Cell Biol, 31, 1279–1284.
22.
SutoA., NakajimaH., HiroseK., SuzukiK., KagamiS., SetoY., HoshimotoA., SaitoY., FosterD.C., and IwamotoI. (2002). Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line C(epsilon) transcription of IL-4-stimulated B cells. Blood, 100, 4565–4573.
23.
TimmermanJ.M., ByrdJ.C., AndorskyD.J., YamadaR.E., KramerJ., MuthusamyN., HunderN., and PagelJ.M. (2012). A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders. Clin Cancer Res, 18, 5752–5760.
24.
TroppanK., WenzlK., DeutschA., LingH., NeumeisterP., and PichlerM. (2014). MicroRNAs in diffuse large B-cell lymphoma: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res, 34, 557–564.
25.
YouY., DengJ., ZhengJ., HuM., LiN., WuH., LiW., LuJ., and ZhouY. (2013). IL-21 gene polymorphism is associated with the prognosis of breast cancer in Chinese populations. Breast Cancer Res Treat, 137, 893–901.
26.
ZengR., SpolskiR., FinkelsteinS.E., OhS., KovanenP.E., HinrichsC.S., Pise-MasisonC.A., RadonovichM.F., BradyJ.N., RestifoN.P., BerzofskyJ.A., and LeonardW.J. (2005). Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med, 201, 139–148.
27.
ZhangJ., XiaoW.X., ZhuY.F., MuhaliF.S., XiaoL., JiangW.J., ShiX.H., ZhouL.H., and ZhangJ.A. (2013). Polymorphisms of interleukin-21 and interleukin-21-receptor genes confer risk for autoimmune thyroid diseases. BMC Endocr Disord 13,26.
